Home›Oncology› Higher serum vitamin D levels linked to small increase in prostate cancer risk
Higher serum vitamin D levels linked to small increase in prostate cancer riskHigher Vitamin D Levels Linked to Increased Prostate Cancer Risk
Frontiers in MedicinePublished July 3, 2026Study authors: Li Wei, Lina Fan, Huifen WangDOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Interpret the small association between higher vitamin D and prostate cancer risk cautiously due to observational data and no linear dose-response.
This umbrella review of systematic reviews and meta-analyses of observational studies examined the association between serum vitamin D levels and prostate cancer incidence. The primary analysis showed a small but statistically significant association between higher serum vitamin D levels and increased prostate cancer risk (OR 1.06, 95% CI 1.02-1.09, p=0.001). However, when analyzing the relative risk per 10-ng/mL increment in serum vitamin D, no significant association was found (RR 1.02, 95% CI 0.99-1.06, p=0.207).
The authors note that the evidence is limited by the observational nature of included studies, potential residual confounding, and modest effect sizes. Importantly, no clear linear dose-response relationship was established, and the findings represent an association rather than a causal link.
Clinically, these results should be interpreted with caution. The small effect size and lack of a consistent dose-response relationship suggest that any potential risk increase is minimal and may not warrant changes in clinical practice regarding vitamin D supplementation or screening. Further research with more rigorous study designs is needed to clarify this association.
How this fits prior evidence
This umbrella review extends prior findings on prostate cancer risk factors. While earlier coverage noted a small PSA rise from catheterisation unlikely to affect clinical decisions, the current review adds that higher serum vitamin D levels are associated with a small increase in prostate cancer risk (OR 1.06). However, unlike the clear malignancy risk (21.3%) from incidental FDG PET/CT uptake, the vitamin D association is modest and lacks a linear dose-response, consistent with the insufficient evidence for causal links seen in occupational hexavalent chromium exposure.
Researchers looked at existing studies to see if there is a connection between vitamin D levels in the blood and the risk of developing prostate cancer. This type of review combined several different observations to find broad patterns.
The analysis found a small but statistically significant link between higher serum vitamin D levels and an increased risk of prostate cancer. However, when researchers looked at specific amounts of vitamin D added to the blood, they did not find a clear pattern or a steady increase in risk as levels went up.
Because these findings come from observational studies rather than controlled trials, it is difficult to say if one thing caused the other. The results are also considered modest. These findings should be viewed with caution because the data does not show a direct link between specific doses and cancer risk.
What this means for you:
A small link was found between higher vitamin D levels and prostate cancer, but more research is needed.
Common questions
Does more vitamin D mean a higher risk of prostate cancer?
The study found a small but statistically significant association between higher serum vitamin D levels and an increased risk of prostate cancer. However, the researchers did not find a clear link when looking at specific amounts added to the blood. Because this is based on observational data, it does not prove that vitamin D causes cancer.
Is there a specific amount of vitamin D that is safe?
The study did not find a clear linear relationship between specific amounts of vitamin D and cancer risk. Because the evidence comes from observational studies rather than controlled trials, it is difficult to determine a specific dose for safety or prevention. You should talk to your doctor about your specific needs.
How strong is the link between vitamin D and prostate cancer?
The study reported a modest effect size with an odds ratio of 1.06. While this was statistically significant, the researchers noted that the results should be interpreted cautiously because the data comes from observational studies and does not show a clear dose-response relationship.
This umbrella review examines the controversial link between serum vitamin D levels and prostate cancer (PC) risk by systematically re-analyzing existing meta-analyses. It aims to synthesize the available evidence while acknowledging the inherent limitations of umbrella reviews and observational data.
A systematic search of PubMed, Scopus, and Web of Science was performed to identify all meta-analyses assessing serum vitamin D levels and PC risk up to January 2025. Eligible studies were observational meta-analyses reporting pooled effect sizes (ORs, RRs, or HRs) to determine the association between circulating vitamin D and PC incidence; however, other types of designs were excluded. Data extraction was performed using a standardized framework. Heterogeneity assessment was performed by utilizing Cochran’s Q test and I2 statistics; Re-analysis of extracted data was conducted using random-effects models, and leave-one-out sensitivity analyses evaluated the stability of pooled associations.
Pooled categorical analyses suggested a small but statistically significant association between higher serum vitamin D levels and increased PC risk (OR: 1.06; 95% CI: 1.02–1.09; p=0.001), with low heterogeneity. Moreover, sensitivity analyses showed consistent findings across individual study exclusions. In contrast, pooled relative risk estimates per 10-ng/mL increment in serum vitamin D did not show a significant association (RR: 1.02; 95% CI: 0.99–1.06; p=0.207). Sensitivity analyses did not materially change these findings.
Higher serum vitamin D levels may be associated with a slightly increased odds of PC in categorical analyses, but the evidence does not support a clear linear dose–response relationship. Given the observational nature of the included evidence, residual confounding, and modest effect sizes, these findings should be interpreted cautiously.
